Monitor for a more detailed press release or subsequent disclosure with efficacy data. Without quantitative results, the market impact is limited to binary speculation on pipeline value.
Price Chart
Executive Summary
Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for systemic sclerosis. The results support the safety and tolerability of ifetroban in this rare disease population. No efficacy data or quantitative results were disclosed, making the clinical significance unclear.
Key Facts
- Phase 2a ASSIST-SSc trial evaluating oral ifetroban for systemic sclerosis
- Top-line results support safety and tolerability of ifetroban
- No efficacy data or quantitative results disclosed in the filing
Financial Impact
No financial figures disclosed; clinical-stage catalyst with no revenue impact from this trial
Risk Factors
- Lack of efficacy data may disappoint if expectations were higher
- Systemic sclerosis is a rare disease with uncertain commercial potential
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (CPIX) — Batch item 1 | 0001087294-26-000070 |
| Document: 0001087294-26-000070-index-headers.html | 0001087294-26-000070 |
| Document: 0001087294-26-000070-index.html | 0001087294-26-000070 |
| Document: 0001087294-26-000070.txt | 0001087294-26-000070 |
| 8-K Filing (CPIX) — Batch item 5 | 0001087294-26-000070 |
| Document: 0001087294-26-000070-index-headers.html | 0001087294-26-000070 |
| Document: 0001087294-26-000070-index.html | 0001087294-26-000070 |
| Document: 0001087294-26-000070.txt | 0001087294-26-000070 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $5.22 | awaiting T+1 | — | $4.75 (−9.00%) |
Oct 23, 2026 3d ago | 8-K | $8.46 | awaiting T+1 | — | $4.75 (−43.85%) |
Aug 28, 2026 8w ago | 8-K | $6.69 $6.56 | ▲ +1.94% | ▲ +1.26% | $4.75 (+29.00%) |
Jul 13, 2026 15w ago | Press Release | $6.54 $6.99 | ▲ +6.80% | ▲ +6.45% | $4.75 (−27.37%) |
May 26, 2026 22w ago | DEFM14A | $5.77 $5.86 | ▲ +1.56% | ▲ +1.55% | $4.75 (−17.68%) |
Apr 23, 2026 26w ago | DEFA14A / 8-K | $3.90 $4.06 | ▲ +4.10% | ▲ +3.32% | $4.75 (+21.79%) |
Mar 9, 2026 33w ago | DEFA14A | $3.16 $3.08 | ▼ −2.53% | ▼ −2.43% | $4.75 (+50.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers